Earli

Earli is a biotechnology company founded in 2018 and based in Redwood City, California, with operations in South San Francisco.

The company focuses on transforming cancer detection and treatment through its innovative Synthetic Biopsy technology. Earli's mission is to make cancer a benign experience by utilizing programmable genetic constructs that enable early detection and self-destruction of tumors. The Synthetic Biopsy platform allows for the detection of cancer at its earliest stages by forcing cancer cells to produce a synthetic biomarker, which can be identified in blood, urine, or breath samples. This technology not only aids in early detection but also facilitates precise localization of tumors using PET scans. Additionally, Earli integrates artificial intelligence to enhance the specificity and efficiency of its genetic constructs, ensuring targeted action against malignant cells while preserving healthy tissue. Earli collaborates with strategic partners and investors, including Accenture Ventures and Andreessen Horowitz, to advance its mission in the healthcare and oncology sectors. The company aims to improve patient outcomes by enabling personalized treatment and early detection of metastases.